Stem cell transplant is a core myeloma therapy and is effective at eliminating the bulk of myeloma cells but residual cells can remain, causing eventual relapse. A new clinical trial is now open that uses an immunotherapy vaccine to go after these residual cells. This is a Phase II, multi-center study (16 centers) that is comparing autologous stem cell transplant and lenalidomide maintenance vs. autologous stem cell transplant, lenalidomide maintenance and the dendritic cell myeloma vaccine. To learn more about this approach, listen to Dr. David Avigan explain this clinical trial on Myeloma Crowd Radio or watch Dr. Avigan on Myeloma Crowd TV (at 16:46). Click here to find the open clinical trial: Dendritic Cell Vaccine with SCT Clinical Trial